IT1277147B1 - Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi. - Google Patents

Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Info

Publication number
IT1277147B1
IT1277147B1 IT95RM000037A ITRM950037A IT1277147B1 IT 1277147 B1 IT1277147 B1 IT 1277147B1 IT 95RM000037 A IT95RM000037 A IT 95RM000037A IT RM950037 A ITRM950037 A IT RM950037A IT 1277147 B1 IT1277147 B1 IT 1277147B1
Authority
IT
Italy
Prior art keywords
carnitine
cyclosporin
derivatives
reduce
toxic effects
Prior art date
Application number
IT95RM000037A
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ITRM950037A0 publication Critical patent/ITRM950037A0/it
Priority to IT95RM000037A priority Critical patent/IT1277147B1/it
Priority to DK95120394T priority patent/DK0722724T3/da
Priority to EP95120394A priority patent/EP0722724B1/en
Priority to ES95120394T priority patent/ES2130509T3/es
Priority to DE69508551T priority patent/DE69508551T2/de
Priority to AT95120394T priority patent/ATE177946T1/de
Priority to TW084113879A priority patent/TW445145B/zh
Priority to US08/580,993 priority patent/US5955424A/en
Priority to CA002167456A priority patent/CA2167456A1/en
Priority to KR1019960001086A priority patent/KR100443730B1/ko
Priority to ZA96431A priority patent/ZA96431B/xx
Priority to JP8008347A priority patent/JPH08231390A/ja
Publication of ITRM950037A1 publication Critical patent/ITRM950037A1/it
Priority to US08/925,485 priority patent/US5958941A/en
Application granted granted Critical
Publication of IT1277147B1 publication Critical patent/IT1277147B1/it
Priority to GR990401622T priority patent/GR3030545T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IT95RM000037A 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi. IT1277147B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
DK95120394T DK0722724T3 (da) 1995-01-20 1995-12-22 Anvendelse af L-carnitin og dets derivater til nedsættelse af de toksiske virkninger af cyclosporin-A og andre immunosuppre
EP95120394A EP0722724B1 (en) 1995-01-20 1995-12-22 Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants
ES95120394T ES2130509T3 (es) 1995-01-20 1995-12-22 Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores.
DE69508551T DE69508551T2 (de) 1995-01-20 1995-12-22 Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
AT95120394T ATE177946T1 (de) 1995-01-20 1995-12-22 Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva
TW084113879A TW445145B (en) 1995-01-20 1995-12-26 Use of L-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-A and other immunodeppressants drugs
US08/580,993 US5955424A (en) 1995-01-20 1996-01-03 Use of L-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-A and other immunosuppressant drugs
CA002167456A CA2167456A1 (en) 1995-01-20 1996-01-17 Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-a and other immunodeppresant drugs
KR1019960001086A KR100443730B1 (ko) 1995-01-20 1996-01-19 사이클로스포린-a와다른면역억제제의독성효과를감소를위한l-카르니틴및알카노일l-카르니틴유도체의용도
ZA96431A ZA96431B (en) 1995-01-20 1996-01-19 Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs
JP8008347A JPH08231390A (ja) 1995-01-20 1996-01-22 カルニチン類を含む医薬組成物
US08/925,485 US5958941A (en) 1995-01-20 1997-09-08 Use of L-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-A and other immunosuppressant drugs
GR990401622T GR3030545T3 (en) 1995-01-20 1999-06-16 Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Publications (3)

Publication Number Publication Date
ITRM950037A0 ITRM950037A0 (it) 1995-01-20
ITRM950037A1 ITRM950037A1 (it) 1996-07-20
IT1277147B1 true IT1277147B1 (it) 1997-11-04

Family

ID=11402949

Family Applications (1)

Application Number Title Priority Date Filing Date
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Country Status (13)

Country Link
US (2) US5955424A (it)
EP (1) EP0722724B1 (it)
JP (1) JPH08231390A (it)
KR (1) KR100443730B1 (it)
AT (1) ATE177946T1 (it)
CA (1) CA2167456A1 (it)
DE (1) DE69508551T2 (it)
DK (1) DK0722724T3 (it)
ES (1) ES2130509T3 (it)
GR (1) GR3030545T3 (it)
IT (1) IT1277147B1 (it)
TW (1) TW445145B (it)
ZA (1) ZA96431B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
IT1306179B1 (it) 1999-07-28 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
HUP0302293A3 (en) * 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
JPH01213258A (ja) * 1988-02-23 1989-08-28 Kyowa Hakko Kogyo Co Ltd カルニチンおよびカルニチンアミドの精製法

Also Published As

Publication number Publication date
GR3030545T3 (en) 1999-10-29
ITRM950037A0 (it) 1995-01-20
US5955424A (en) 1999-09-21
ITRM950037A1 (it) 1996-07-20
JPH08231390A (ja) 1996-09-10
DE69508551T2 (de) 1999-09-02
TW445145B (en) 2001-07-11
DK0722724T3 (da) 1999-10-11
US5958941A (en) 1999-09-28
DE69508551D1 (de) 1999-04-29
ES2130509T3 (es) 1999-07-01
EP0722724B1 (en) 1999-03-24
EP0722724A1 (en) 1996-07-24
KR100443730B1 (ko) 2004-10-14
ATE177946T1 (de) 1999-04-15
CA2167456A1 (en) 1996-07-21
ZA96431B (en) 1996-08-08
KR960029314A (ko) 1996-08-17

Similar Documents

Publication Publication Date Title
IT1277147B1 (it) Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
DK44791A (da) Behandling af beskadiget knoglemarv
NO975709D0 (no) Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter
CA2209001A1 (en) Hydrophobic taxane derivatives
CA2235375A1 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
DE69425304T2 (de) Zyklische antimikrobielle Peptide und deren Herstellung
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
KR910019618A (ko) 발기부전증 치료용 제약 조성물
DE69322251D1 (de) Medizinische zusammensetzung
DE69222698D1 (de) 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze
NO995127D0 (no) Stabiliserte tibolonblandinger
ZA9110037B (en) The use of acetyl l-carnitine in the therapeutic treatment of coma and pharmacological compositions useful in such treatment
DE69417169D1 (de) Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex
ATE169922T1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
Cherkasova et al. Potential-operated calcium channels and heart contractility function during toxic shock caused by mouse toxin Yersinia pestis.
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi
DK0615446T3 (da) Retard-lægemiddel indeholdende et dihydropyridinderivat i nanosolform og fremstilling heraf
KR930004460A (ko) 에이(a) 87689 화합물
TH33442A (th) อนุพันธ์ของเตตร้าไฮโดรไอโดรไอโซควิโนลีน
MX9303606A (es) Derivados de azabicicloheptano n-sustituidos, su obtencion y uso.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971205